Janssen's Zytiga Shines At ASCO But Prostate Cancer Pipeline Progress May Dampen Impact

 
• By Lucie Ellis-Taitt
  
Conference
Janssen reports data for Zytiga triplet in early-stage prostate cancer at ASCO 2017 • Source: Mary Jo Laffler
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D